The protective effects of rutaecarpine on gastric mucosa injury in rats.
Previous investigations have shown that calcitonin gene-related peptide (CGRP) protects gastric mucosa against injury induced by acetylsalicylic acid (ASA) and that rutaecarpine activates vanilloid receptors to evoke CGRP release. In the present study, we examined the protective effects of rutaecarpine on gastric mucosa injury, and explored whether the protective effects of rutaecarpine are related to stimulation of endogenous CGRP release via activating vanilloid receptors in rats. In an ASA-induced ulceration model, gastric mucosal ulcer index, pH value of gastric juice and plasma concentrations of CGRP were determined. ASA significantly increased the gastric mucosal ulcer index and the back-diffusion of H+ through the mucosa. Rutaecarpine at the doses of 100 or 300 microg/kg (i.v.), and 300 or 600 microg/kg (intragastric, i.g.) reduced the ulcer index and back-diffusion of H+, which was abolished by pretreatment with capsaicin (50 mg/kg, s.c.) or capsazepine (3 mg/kg, i.v.), a competitive vanilloid receptor antagonist. Rutaecarpine significantly increased the plasma concentration of CGRP, which was also abolished by capsazepine. In a stress-induced ulceration model, rutaecarpine reduced gastric mucosal damages, which was abolished by capsazepine (5 mg/kg, i.p.). These results suggest that rutaecarpine protects the gastric mucosa against injury induced by ASA and stress, and that the gastroprotective effect of rutaecarpine is related to a stimulation of endogenous CGRP release via activation of the vanilloid receptor.
Wang
Li
L
Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, PR China.
Hu
Chang-Ping
CP
Deng
Pan-Yue
PY
Shen
Shen-Si
SS
Zhu
Hui-Qing
HQ
Ding
Jin-Song
JS
Tan
Gui-Shan
GS
Li
Yuan-Jian
YJ
D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001241:Aspirin; D004195:Disease Models, Animal; D032086:Evodia; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D026121:Indole Alkaloids; D008297:Male; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines; D051381:Rats; D017207:Rats, Sprague-Dawley; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D052999:Quinazolinones
D000470:Alkaloids; D000897:Anti-Ulcer Agents; D001241:Aspirin; D026121:Indole Alkaloids; D010936:Plant Extracts; D011799:Quinazolines; C028632:rutecarpine; D052999:Quinazolinones